Clinical Trial Update: HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC

View source ↗

Summary

This clinical trial update discusses HBV-host cfDNA as a minimal residual tumor marker for HBV-related hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Carcinoma, Hepatocellular | Status: UNKNOWN